Data as of Dec 06
| -0.01 / -1.39%|
Titan Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of products for the treatment of central nervous system disorders, cardiovascular disease and cancer. Its product development programs focus primarily on large pharmaceutical markets with significant unmet medical needs and commercial potential. The company's products include Fanapt and Probuphine. Fanapt is a typical antipsychotic compound approved in the U.S. for the treatment of schizophrenia. Probuphine is a slow release implant formulation of buprenorphine that is capable of maintaining a stable, round the clock blood level of the medicine in patients for six months following a single treatment. It is in phase 3 clinical development for the treatment of opioid addiction. Titan Pharmaceuticals was founded by Louis R. Bucalo in 1992 and is headquartered in South San Francisco, CA.
|Sunil Bhonsle||President, Secretary & Director|
|Brian Crowley||Vice President-Finance|
|Katherine L. Beebe||Chief Development Officer & Executive VP|
|Richard C. Allen||Executive Vice President-Cell Therapy|